Malignant Advanced Solid Tumor
Conditions
Brief summary
Phase I dose escalating trial. Primary objectives of this study are to assess the safety and tolerability of Simmiparib following single and multiple oral doses in patients with advanced solid malignancies, to determine the maximum tolerance dose (MTD) and dose limiting toxicity (DLT), and pharmacokinetic profile. The Secondary objective is to observe the preliminary antitumor effect of Simmiparib.
Detailed description
This single-center, nonrandomized, open-label, dose-escalating study. The trial was divided into dose escalation and expansion stages.
Interventions
DRUGSimmiparib
Simmiparib Tablets, oral administration
Sponsors
Shanghai Acebright Pharmaceuticals Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients confirmed with advanced solid tumor based on pathology and/or cytology, considered unresponsive or poorly responsive to standard therapies, no curative therapies or can't tolerate standard therapies; 2. Patients must have measurable disease in accordance with RECIST criteria v. 1.1, at least one lesion that can be accurately measured in CT and MRI at least one dimension ( longest diameter≥10mm; if lymph node, short diameter≥15mm ); 3. Age≥18 and ≤75 years, both men and women, no history of drug abuse and alcohol; 4. Life expectancy≥ 3 months and can be followed for safety and efficiency 5. Received no prior anti-tumor therapies at least within past 4 weeks and no other adjuvant anti-tumor regimen(including steroids mediations ) 6. Have recovered to≤ common terminology criteria of adverse events (CTC-AE) 1 from toxicities of prior therapy 7. Not participated in any clinical trials within 28 days; 8. Not have received treatment of poly-ADP ribose polymerase (PARP) inhibitor; 9. No serious abnormal hematopoiesis function, has adequate cardiac, pulmonic, hepatic and renal function. Blood routine and blood biochemical examination within 2 weeks before enrollment : White blood cell (WBC) ≥4000/mm3, Absolute neutrophil count (ANC) ≥1,500/mm3, Platelets ≥100,000/mm3, Coagulation function ≤ 1.5 times upper limit of normal (ULN), serum creatinine ≤ 1.5 times ULN, Total bilirubin ≤ 1.5 times ULN, Patients without liver metastasis, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)≤ 2.5 times ULN; Patients with liver metastasis, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/≤ 2.5 times ULN, NYHAclass≤Ⅱand Left ventricular ejection fraction ( LVEF)\>50%; 10. Virology test: negative HbsAg, HCV, HIV and syphilis 11. Eastern Cooperative Oncology Group(ECOG) performance status ≤2; 12. No history of other malignant tumors, except cervical carcinoma in situ, basal skin cancer or squamous-cell carcinoma that have been cured; No other serious illnesses that are in conflict with this study and significant heart disease and psychosis; 13. Ability to understand and a willingness to sign a written informed consent; Obtaining consent before any operation
Exclusion criteria
1. Patients with serious medical disease, including, severe cardiopathy, vascular disease, uncontrolled diabetes, uncontrolled hypertension, severe infection , or psychosis, etc.; 2. Patients with primary brain lesion or metastases lesion; 3. Female patient who is pregnant, breast feeding or unwilling to contraception; 4. Patient who received or is receiving any other investigational agents within 4 weeks prior to treatment; 5. Patients, with poor compliance, or based on the opinion of the investigator, should not be enrolled into this study; 6. has not recovered to grade 1 or better from any adverse events related to previous therapy. 7. Neurotoxicity observed in previous antineoplastic therapy has not recovered to grade 1 or below.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) | Per doselevel of 3 to 6 patients (When 3-6 patients have completed DLT periods of 4 weeks) | The Dose level at which more than 1/6 patients develop a Dose Limiting Toxicity (DLT) |
| Pharmacokinetic Cmax (maximum concentration) | At day 1 single dose period, day 8 and 28 multiple dose period day | PK blood collection Before 0:00h and after 0.25h、0.50h、1:00h、1.50h、2:00h、3:00h、4:00h、6:00h、8:00h、10:00h、24:00h、48:00h、72:00h at single dose period. PK blood collection before 0:00h and after 0.25h、0.50、1:00h、1.50h、2:00h、3:00h、4:00h、6:00h、8:00h、10:00h and 12:00h at multiple dose period |
| Pharmacokinetic Tmax (Time of maximum concentration) | At day 1 single dose period, day 8 and 28 multiple dose period day | — |
| Pharmacokinetics AUC (Area Under the Curve) | At day 1 single dose period, day 8 and 28 multiple dose period day | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Poly ADP-ribose polymerase (PARP) inhibition measured by PAR assay | Up to 4 months | — |
| Overall Response Rate (ORR) | Up to 4 months | ORR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) |
Countries
China
Contacts
Primary ContactMohammadAbdul Kaium
Backup ContactJian Liu
Outcome results
None listed